Drug Trial Radar · NCT01659255
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL
Last checked: Nov 20, 2026Latest source record: Mar 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Aug 17, 2012
Primary completion
Feb 23, 2015
Study completion Jan 11, 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Ono Pharmaceutical Co., Ltd.
- First posted
- Aug 7, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and tolerability of tirabrutinib (formerly ONO/GS-4059) given as monotherapy to participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Conditions
- Non Hodgkins Lymphoma
- Chronic Lymphocytic Leukaemia
Interventions
TirabrutinibDrug
Capsules administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Dose-Limiting ToxicitiesTime frame: Day 1 through Day 28
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
CHRU - Hopital Claude HURIEZ
Lille, France
Centre hospitalier Lyon Sud
Lyon, France
CHU St Eloi
Montpellier, France
University Hospital of Wales
Cardiff, United Kingdom
Leicester Royal Infirmary
Leicester, United Kingdom
Derriford Hospital
Plymouth, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.